Loading
A rare cancer drug designated 'orphan' in the US must reapply in Europe, Japan and elsewhere. Recognising each other's decisions would save small companies months.
Orphan designation (FDA, EMA, MHLW, others) grants fee waivers, protocol assistance and exclusivity, and is applied for separately with different prevalence thresholds and evidence formats. FDA and EMA offer a common application form but decide independently. The proposal is reciprocal recognition: a designation from one stringent regulator is accepted by partners on notification, with local prevalence data required only where the condition's epidemiology plausibly differs.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Regulatory divergence between regions, Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets.
Shares Regulatory divergence between regions, Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets.